Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H30O6 |
Molecular Weight | 402.4807 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](C(=O)COC(C)=O)[C@]1(C[C@H](O)[C@@]3([H])[C@@]2([H])CCC4=CC(=O)CC[C@]34C)C=O
InChI
InChIKey=HCJKXXMOOMBBPY-IEJDVFFQSA-N
InChI=1S/C23H30O6/c1-13(25)29-11-20(28)18-6-5-17-16-4-3-14-9-15(26)7-8-22(14,2)21(16)19(27)10-23(17,18)12-24/h9,12,16-19,21,27H,3-8,10-11H2,1-2H3/t16-,17-,18+,19-,21+,22-,23+/m0/s1
Molecular Formula | C23H30O6 |
Molecular Weight | 402.4807 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Aldosterone is a hormone secreted by the adrenal cortex that regulates electrolyte and water balance by increasing the renal retention of sodium and the excretion of potassium. Recent findings have shown that the physiological functions of the hormone aldosterone go far beyond its well-known role in blood-pressure regulation and salt/water homeostasis. Aldosterone is for example involved in the regulation of inflammation, and also binds directly to mineralocorticoid receptors in specific brain regions. At the late distal tubule and collecting duct, aldosterone has two main actions: 1) aldosterone acts on mineralocorticoid receptors (MR) on principal cells in the distal tubule of the kidney nephron, increasing the permeability of their apical (luminal) membrane to potassium and sodium and activates their basolateral Na+/K+ pumps, stimulating ATP hydrolysis leading to phosphorylation of the pump and a conformational change in the pump exposes the Na+ ions to the outside. The phosphorylated form of the pump has a low affinity for Na+ ions, hence reabsorbing sodium (Na+) ions and water into the blood, and secreting potassium (K+) ions into the urine; 2) aldosterone stimulates H+ secretion by intercalated cells in the collecting duct, regulating plasma bicarbonate (HCO3−) levels and its acid/base balance; and 3) aldosterone may act on the central nervous system via the posterior pituitary gland to release vasopressin (ADH) which serves to conserve water by direct actions on renal tubular resorption.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21375792 | https://www.ncbi.nlm.nih.gov/pubmed/18377905
Curator's Comment: Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder in rodent models.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1994 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26907965 |
3.8 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Metabolic alkalosis. | 2001 Apr |
|
Intrarenal angiotensin and bradykinin peptide levels in the remnant kidney model of renal insufficiency. | 2001 Apr |
|
Prolonged orexin administration stimulates steroid-hormone secretion, acting directly on the rat adrenal gland. | 2001 Apr |
|
Mineralocorticoid and glucocorticoid receptors inhibit UCP expression and function in brown adipocytes. | 2001 Apr |
|
Local inhibition of nitric oxide temporarily stimulates aldosterone secretion in conscious sheep in vivo. | 2001 Apr |
|
The serum- and glucocorticoid-induced kinase is a physiological mediator of aldosterone action. | 2001 Apr |
|
Regulation of calcitonin receptor by glucocorticoid in human osteoclast-like cells prepared in vitro using receptor activator of nuclear factor-kappaB ligand and macrophage colony-stimulating factor. | 2001 Apr |
|
Minireview: 11beta-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action. | 2001 Apr |
|
Aldosterone induces rapid apical translocation of ENaC in early portion of renal collecting system: possible role of SGK. | 2001 Apr |
|
Additional beneficial effects of canrenoate in patients with anterior myocardial infarction on ACE-inhibitor treatment. A pilot study. | 2001 Feb |
|
Volume-induced natriuresis in healthy women: renal metabolism of prostacyclin and thromboxane, and physiological role of prostanoids. | 2001 Feb |
|
K(+) depletion and the progression of hypertensive disease or heart failure. The pathogenic role of diuretic-induced aldosterone secretion. | 2001 Feb |
|
Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. | 2001 Feb |
|
Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats. | 2001 Feb |
|
Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. | 2001 Feb |
|
C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. | 2001 Feb |
|
Workshop: mechanisms and cardiovascular damage in hypertension. | 2001 Feb |
|
Effect of furosemide on renal excretion of oxypurinol and purine bases. | 2001 Feb |
|
Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. | 2001 Feb |
|
Multiple aspects of mineralocorticoid selectivity. | 2001 Feb |
|
alpha1H T-type Ca2+ channel is the predominant subtype expressed in bovine and rat zona glomerulosa. | 2001 Feb |
|
Steroids differentially inhibit the nicotinic acetylcholine receptor. | 2001 Feb 12 |
|
Lack of toxic effects of F 12511, a novel potent inhibitor of acyl-coenzyme A: cholesterol O-acyltransferase, on human adrenocortical cells in culture. | 2001 Feb 15 |
|
Molecular mechanisms of human hypertension. | 2001 Feb 23 |
|
Differential effects of agonists of aldosterone secretion on steroidogenic acute regulatory phosphorylation. | 2001 Feb 28 |
|
[Effect of aldosterone antagonism in heart failure: pharmacotherapeutic options]. | 2001 Feb 3 |
|
Renal function, sodium and water homeostasis in patients with idiopathic extrahepatic portal vein thrombosis compared with normal healthy controls. | 2001 Jan |
|
Tackling polycystic ovary syndrome. | 2001 Jan |
|
Preformulation experiences and in vitro model studies with spironolactone-containing suppositories. | 2001 Jan |
|
Diagnosis and management of congenital adrenal hyperplasia: clinical, molecular and prenatal aspects. | 2001 Jan-Feb |
|
Slowing the progression of CHF. Drug therapy to correct neurohormonal abnormalities. | 2001 Mar |
|
Nesiritide for the treatment of decompensated heart failure. | 2001 Mar |
|
Effect of chronic oral administration of a low dose of captopril on sodium appetite of hypothyroid rats. Influence of aldosterone treatment. | 2001 Mar |
|
Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens. | 2001 Mar |
|
Modulation of transalveolar fluid absorption by endogenous aldosterone in adult rats. | 2001 Mar |
|
Pathogenesis and management of sodium and water retention in cardiac failure and cirrhosis. | 2001 Mar |
|
Adverse cardiac effects of salt with fludrocortisone in hypertension. | 2001 Mar |
|
Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. | 2001 Mar |
|
Water metabolism disturbances at different stages of primary thyroid failure. | 2001 Mar |
|
Comparison of sympathetic modulation induced by single oral doses of mibefradil, amlodipine, and nifedipine in healthy volunteers. | 2001 Mar |
|
A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension. | 2001 Mar |
|
Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. | 2001 Mar |
|
Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. | 2001 Mar |
|
Approach to the patient with hypertension, unexplained hypokalemia, and metabolic alkalosis. | 2001 Mar |
|
Salt intake and body fluid volumes: have we learned all there is to know? | 2001 Mar |
|
Two sporadic cases of Liddle's syndrome caused by De novo ENaC mutations. | 2001 Mar |
|
Inhibition of aldosterone production in rat adrenal mitochondria by 18-ethynyl-11-deoxycorticosterone: a simple model for kinetic interpretation of mechanism-based inhibitors. | 2001 Mar |
|
The release of antidiuretic hormone is appropriate in response to hypovolemia and/or sodium administration in children with severe head injury: a trial of lactated Ringer's solution versus hypertonic saline. | 2001 Mar |
|
Non-genomic actions of aldosterone: role in hypertension. | 2001 Mar |
|
Effect of therapeutic ultrasound on partition and diffusion coefficients in human stratum corneum. | 2001 Mar 12 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11744652
Horses: Aldosterone was injected intravenously for 6 h at 20-min intervals (total 5.4 ug/kg body wt).
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29180329
Curator's Comment: Cultured neonatal rat ventricular cardiomyocytes were stimulated in vitro with 1 umol/L aldosterone for 24 h. Aldosterone modulates the expression of cardiac voltage-operated Ca2+ channels and accelerates beating in cultured neonatal rat ventricular myocytes. v
Aldosterone within the concentration range of 0.01-1.0 umol/L stimulates the proliferation and osteogenic gene expressions and enhances α-ENaC gene expression in rat osteoblasts in vitro, suggesting the possibility that ENaC participates in aldosterone-mediated regulation of osteoblast functions.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:20:05 GMT 2023
by
admin
on
Fri Dec 15 15:20:05 GMT 2023
|
Record UNII |
RH7JOB7P70
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
73857
Created by
admin on Fri Dec 15 15:20:06 GMT 2023 , Edited by admin on Fri Dec 15 15:20:06 GMT 2023
|
PRIMARY | |||
|
DTXSID701043375
Created by
admin on Fri Dec 15 15:20:06 GMT 2023 , Edited by admin on Fri Dec 15 15:20:06 GMT 2023
|
PRIMARY | |||
|
297-91-6
Created by
admin on Fri Dec 15 15:20:06 GMT 2023 , Edited by admin on Fri Dec 15 15:20:06 GMT 2023
|
PRIMARY | |||
|
RH7JOB7P70
Created by
admin on Fri Dec 15 15:20:06 GMT 2023 , Edited by admin on Fri Dec 15 15:20:06 GMT 2023
|
PRIMARY | |||
|
101637
Created by
admin on Fri Dec 15 15:20:06 GMT 2023 , Edited by admin on Fri Dec 15 15:20:06 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |